Abstract
Molecular target-based drugs have been expected as promising drugs in cancer treatment, and clinical trials using combined radiation therapy plus molecular target-based drugs have been performed to evaluate the feasibility and efficacy of this approach. In order to obtain maximum radiotherapeutic gain, a detailed understanding of the mechanism underlying the interaction between radiation and these drugs is indispensable. Preclinical data have already demonstrated synergistic enhancement of radiation-induced cell killing by several molecular target-based drugs, such as EGFR inhibitors. Among these, the effect of drugs targeted against receptor tyrosine kinase and its signal transduction pathways on the radiosensitivity has been intensively investigated. In this review, established and potential molecular targets for potentiation of radiation-induced cell killing are summarized, especially focusing on EGFR and its signal transduction pathways; also, clinical trials of combined radiation therapy plus molecular-target drug therapy are summarized.
Keywords: EGFR, molecular target, radiation, radiosensitivity
Current Signal Transduction Therapy
Title: Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes
Volume: 5 Issue: 3
Author(s): Tetsuo Akimoto and Norio Mitsuhashi
Affiliation:
Keywords: EGFR, molecular target, radiation, radiosensitivity
Abstract: Molecular target-based drugs have been expected as promising drugs in cancer treatment, and clinical trials using combined radiation therapy plus molecular target-based drugs have been performed to evaluate the feasibility and efficacy of this approach. In order to obtain maximum radiotherapeutic gain, a detailed understanding of the mechanism underlying the interaction between radiation and these drugs is indispensable. Preclinical data have already demonstrated synergistic enhancement of radiation-induced cell killing by several molecular target-based drugs, such as EGFR inhibitors. Among these, the effect of drugs targeted against receptor tyrosine kinase and its signal transduction pathways on the radiosensitivity has been intensively investigated. In this review, established and potential molecular targets for potentiation of radiation-induced cell killing are summarized, especially focusing on EGFR and its signal transduction pathways; also, clinical trials of combined radiation therapy plus molecular-target drug therapy are summarized.
Export Options
About this article
Cite this article as:
Akimoto Tetsuo and Mitsuhashi Norio, Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes, Current Signal Transduction Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157436210791920274
DOI https://dx.doi.org/10.2174/157436210791920274 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Celecoxib as a Potential Inhibitor in the Treatment of
Inflammatory Diseases - A Review
Current Medicinal Chemistry Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets Oxidative Stress and Cancer: The Role of Nrf2
Current Cancer Drug Targets Stage N2/IIIA Non Small Cell Lung Cancer: An Evidence-Based Review
Current Cancer Therapy Reviews Role of Phase II Drug Metabolizing Enzymes in Cancer Chemoprevention
Current Drug Metabolism Acute Lymphoblastic Leukemia and Regulatory T cells: Biomarkers and Immunopathogenesis
Current Immunology Reviews (Discontinued) Current and Emerging Therapies in Primary Myelofibrosis
Cardiovascular & Hematological Disorders-Drug Targets The Extracapsular Lymph Node Extension Predicts Outcomes in Colorectal Cancer: A Short Review
Current Drug Targets Editorial [Hot Topic: Tumor Immunology (Guest Editors: Bharat H. Joshi and Raj K. Puri)]
Current Molecular Medicine Selective Inhibition of Esophageal Cancer Stem-like Cells with Salinomycin
Anti-Cancer Agents in Medicinal Chemistry Lipid Nanoparticles to Deliver miRNA in Cancer
Current Pharmaceutical Biotechnology The Role of Chemotherapy and Radiation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Small-molecule Inhibitors of Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinases (TK)
Current Pharmaceutical Design Recent Advance in Drug Development of Squamous Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Current Pharmacogenomics and Personalized Medicine Impact of PLK-1 Silencing on Endothelial Cells and Cancer Cells of Diverse Histological Origin
Current Gene Therapy Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin
Current Pharmaceutical Biotechnology Hypertension, Anti-Hypertensive Therapy and Neoplasia
Current Pharmaceutical Design Bile Acids and Derivatives, Their Nuclear Receptors FXR, PXR and Ligands: Role in Health and Disease and Their Therapeutic Potential
Anti-Cancer Agents in Medicinal Chemistry